By

Gisela Pairo
Children’s Tumor Foundation president, Annette Baker talked to the Innovative Medicines Initiative (IMI) about EU-PEARL and the vital alliance of public and private players to achieve real impact. CTF is non-profit Associated Partner at EU-PEARL. It co-leads the work package focused on developing a platform trial for Neurofibromatosis. Read full interview 
Read More
With the motto “Inspire, Engage, Enable and Transform”,  EU-PEARL held its 3rd General Assembly Meeting from 8th to 10th June. Over 200 participants connected to the different sessions organised over 3 half days to advance in the design of Integrated Research Platforms (IRPS). This innovative framework will make it easier for different companies and organisations...
Read More
by Traceann Rose, Director Patient Engagement, Children’s Tumor Foundation Patients need to have a voice and be a part of the research process because scientists and researchers don’t always know what the other side is experiencing. This underscores the value of patient involvement in research projects and the shift from patients being subject to research...
Read More
by Hannes Jarke, Project Coordinator, European Patients’ Forum The core of the EU-PEARL initiative is to revolutionise the way clinical trials are conducted by making them more efficient and patient friendly through allowing multiple intervention developers to test their candidate drugs simultaneously against a shared placebo group. The conclusion of EU-PEARL will see sustainable and...
Read More
Riccardo Alagna, Molecular Biologist and public health expert at the Università Vita-Salute San Raffaele of Milan, and member of EU-PEARL will present the “Handbook for capacity building and site readiness assessment for tuberculosis platform trials” at this year’s European Society of Mycobacteriology (ESM) congress, which will be held from June 28-29 in a virtual format....
Read More
On occasion of NASH Day, we talk to EU-PEARL specialists on Nonalcoholic fatty liver disease Juan M. Pericás and Jesús M. Rivera (VHIR) to learn more about NASH. We also ask them where we are in the fight against this disease and how EU-PEARL is contributing to improve prospects for NASH patients. Today is NASH...
Read More
EU-PEARL will present the latest advancements made on the statistical and methodological side of the IRP solution during the upcoming PSI (Statisticians in the Pharmaceutical Industry) 2021 Conference .The event will take place between 21st and 23rd of June in a virtual format. The PSI conference is an important annual event for statisticians in the...
Read More
This question was answered in the manuscript “Identifying challenges in neurofibromatosis: a modified Delphi procedure”, which was published in the European Journal of Human Genetics on April 26th 2021. Britt A. E. Dhaenens, Rosalie E. Ferner, Annette Bakker, Marco Nievo, D. Gareth Evans, Pierre Wolkenstein, Cornelia Potratz, Scott R. Plotkin, Guenter Heimann, Eric Legius and...
Read More
Britt Dhaenens, MD and PhD student at Erasmus University Medical Center (The Netherlands) shares in this interview her amazing journey from patient to researcher. She tells us about her experience in EU-PEARL; the challenges she is contributing to address and the implications for rare diseases patients.  What ignited your scientific vocation? I have been interested...
Read More
On occasion of International Clinical Trial Day (ICTD) we have asked Dr. Burç Aydin, Project Manager at ECRIN and EU-PEARL member, to share his views on the challenges and new opportunities platform trials entail for the future of clinical research. What is the purpose of the ECRIN International Clinical Trials Day? ECRIN launched International Clinical...
Read More
1 2 3 4 5 7

Sign up to stay informed


    We will process your data to deliver our quarterly updates to your inbox. You can view our Privacy Policy here or contact us at info@eu-pearl.eu